M&A Deal Summary |
|
|---|---|
| Date | 2022-02-03 |
| Target | Rewrite Therapeutics |
| Sector | Life Science |
| Buyer(s) | Intellia Therapeutics |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Arnold & Porter Wilson Sonsini Goodrich & Rosati (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
| Employees | 403 |
| Revenue | 58M USD (2024) |
Intellia Therapeutics is a clinical-stage genome editing company, developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia Therapeutics was founded in 2014 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
